topic

590 Clinical outcomes and translational analysis of DART S1609: the thyroid cancer cohort; PD-1+ PD-L1+ TIL correlated with favorable survival
Young Kwang Chae, Yichen Lu, Sandip P Patel, Cristina Rodriguez, Adedayo Onitilo, Ahmad Mattour, Igor Rybkin, Sarah Fenton, Liam Il-Young Chung, Hye Sung Kim, Megan Othus, Edwin Roger Parra, Jiexin Zhang, Lorena Isabel Gomez Bolanos, Caddie Laberiano Fernandez, Luisa Solis Soto, Hong Chen, Ganiraju Manyam, Dzifa Y Duose, Rajyalakshmi Luthra, Jianhua Zhang, Gheath Al-Atrash, Ignacio Wistuba, Jack Lee, Jianjun Zhang, Cara Haymaker, Christine McLeod, Helen Chen, Elad Sharon, Christopher Ryan, Melissa Plets, Gabby Lopez, Charles Blanke, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A671-A672; DOI: 10.1136/jitc-2023-SITC2023.0590
592 Updated recurrence free survival for neoadjuvant bintrafusp alfa (BA) for HPV unrelated HNSCC and results from BA plus a multitargeted recombinant adenovirus 5 vaccine for HPV unrelated HNSCC
Jason M Redman, Lisa Cordes, Seth M Steinberg, Jennifer Marte, Elizabeth Lamping, Charalampos Floudas, Jeffrey Schlom, James L Gulley, Clint Allen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A673; DOI: 10.1136/jitc-2023-SITC2023.0592
593 Efficacy of invariant natural killer T cell infusion plus transarterial embolization vs transarterial embolization alone for hepatocellular carcinoma patients: a phase 2 randomized clinical trial
Jia Guo, Xuli Bao, Fuquan Liu, Jiang Guo, Yifan Wu, Fang Xiong, Jun Lu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A674-A675; DOI: 10.1136/jitc-2023-SITC2023.0593
594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16⁺ tumors treated with cell-based vaccine, SQZ-PBMC-HPV
Antonio Jimeno, Wade T Iams, Jong Chul Park, Monica MitaSc, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Matthew H Taylor, E Amanda Duvall, Julia Jennings, Nathan Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Joaquina Baranda

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A676; DOI: 10.1136/jitc-2023-SITC2023.0594
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
Martin Forster, Enriqueta Felip, Margarita Majem, Bernard Doger, Tim Clay, Enric Carcereny, Igor Bondarenko, Julio Peguero, Manuel Cobo Dols, Grygorii Ursol, Ewa Kalinka, Gema Garcia Ledo, Laia Vilà Martinez, Matthew Krebs, Wade T Iams, Christian Mueller, Chrystelle Brignone, Frederic Triebel

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A677; DOI: 10.1136/jitc-2023-SITC2023.0595
596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy
Diwakar Davar, Zeynep Eroglu, Mohammed Milhem, Carlos Becerra, Martin Gutierrez, Antoni Ribas, Brian Di Pace, Tianli Wang, Hailei Zhang, Srimoyee Ghosh, Shyam Srivats, Arindam Dhar, Theo Borgovan, Angela Waszak, Patricia LoRusso

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A678; DOI: 10.1136/jitc-2023-SITC2023.0596
597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer
Dániel Deme, Bala Öven, Erdem Göker, Istvan Lang, Patrick Brück, Michael Wenger, Neru Munshi, Thomas Schell, Kezi Ünsal-Kaçmaz, Janet Markman, Petra Rietschel, Huyuan Yang, Oezlem Tuereci, Ugur Sahin, Akin Atmaca, Patrick Forde

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A679; DOI: 10.1136/jitc-2023-SITC2023.0597
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Gro Gausdal, David R Micklem, Magnus Blø, Austin Rayford, Dina Alzhanova, Noëlly Madeleine, Josephine Amalia Taverna, Chia-Nung Hung, Rolf A Brekken, Michael Chisamore, Claudia Gorcea-Carson, Cristina Oliva, Nigel McCracken

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A680-A681; DOI: 10.1136/jitc-2023-SITC2023.0598
599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors
Kai He, Meredith McKean, Rama Balaraman, Satish Shah, Edward Arrowsmith, Julio Peguero, John Hamm, Aiwu He, Alexander I Spira, Adriana millillo-Naranine, Rohit Joshi, Mark Goldstein, David Carbone, Mei Tang, Siwen Hu-Lieskovan, Zihai Li, Dan Chen, Hung-Yen Chou, John Yang, Yang Liu, Pan Zheng, Tianhong Li

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A682; DOI: 10.1136/jitc-2023-SITC2023.0599
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
Saadettin Kilickap, Ahmet Sezer, Mahmut Gümü&scedil;, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A683; DOI: 10.1136/jitc-2023-SITC2023.0600

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages